Incyte Partners With Genmab on Metastatic Colorectal Cancer Trial

Bitget2026/10/24 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Incyte and Genmab entered a clinical trial collaboration targeting KRAS G12D-mutated metastatic colorectal cancer.
The Phase 1/2 trial will evaluate INCB161734 with petosemtamab and standard chemotherapy as a first-line treatment.
Genmab will conduct the study; its partner will co-fund it and supply INCB161734.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261024426058) on October 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Incyte Partners With Genmab on Metastatic Colorectal Cancer Trial

You may also like

Crypto prices